uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
A Proposal for an Individualized Pharmacogenetics-Based Warfarin Initiation Dose Regimen for Patients Commencing Anticoagulation Therapy
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Clinical Pharmacology.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Clinical pharmacogenomics and osteoporosis.ORCID iD: 0000-0002-6368-2622
Show others and affiliations
2011 (English)In: Clinical Pharmacology and Therapeutics, ISSN 0009-9236, E-ISSN 1532-6535, Vol. 90, no 5, 701-706 p.Article in journal (Refereed) Published
Abstract [en]

A significant proportion of the interindividual variability in warfarin dose requirements can be explained on the basis of CYP2C9 and VKORC1 genotypes. We report the development of a novel pharmacogenetics-based 3-day warfarin initiation dose (ID) algorithm based on the International Warfarin Pharmacogenetics Consortium (IWPC) maintenance dose algorithm and the CYP2C9 genotype-based variance in warfarin half-life. The predictive value of the pharmacogenetics-based ID was assessed in a large cohort of 671 newly diagnosed patients with thromboembolic disorders who were about to commence anticoagulation therapy in accordance with standard induction regimens. In patients with mean international normalized ratio (INR)(days 4-7)>4.0 (n = 63) after warfarin initiation, the pharmacogenetics-based ID algorithm predicted a markedly lower dose requirement (median reduction = 4.2 mg), whereas in those with mean INR(days 4-7) < 2.0 (n = 145), the predicted dose requirement was very similar to that in the standard regimen. The use of a pharmacogenetics-based ID may avoid overshooting of INR in warfarin-sensitive patients without unduly affecting the time taken to reach target range in the majority of patients.

Place, publisher, year, edition, pages
2011. Vol. 90, no 5, 701-706 p.
National Category
Medical and Health Sciences
URN: urn:nbn:se:uu:diva-161917DOI: 10.1038/clpt.2011.186ISI: 000296420700026OAI: oai:DiVA.org:uu-161917DiVA: diva2:458832
Available from: 2011-11-24 Created: 2011-11-21 Last updated: 2016-02-19

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Hamberg, Anna-KarinWadelius, Mia
By organisation
Clinical PharmacologyClinical pharmacogenomics and osteoporosis
In the same journal
Clinical Pharmacology and Therapeutics
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 166 hits
ReferencesLink to record
Permanent link

Direct link